Upadacitinib in active non-radiographic axial spondyloarthritis: 1-year data from a double-blind, randomized, placebo-controlled, Phase 3 trial

The 1-year results of the SELECT-AXIS 2 study showed significant improvements in ASAS40 achievement in patients with nr-axSpA that were treated with upadacitinib 15mg QD versus placebo. Improvements in ASDAS endpoints, back pain, BASFI, and hsCRP from baseline were also observed.

Van den Bosch, et al. randomised patients with nr-axSpA 1:1 to upadacitinib 15mg QD or placebo and measured a range of endpoints through 52 weeks. Endpoints included ASAS40, ASDAS ID, ASDAS LDA, and changes from baseline in back pain, nocturnal back pain, and BASFI.